Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 35Active not recruiting 30Completed 7Terminated 2Not yet recruiting 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Oropharyngeal Neoplasms 1Carcinoma 1

Interventions

Specimen Handling 28Magnetic Resonance Spectroscopy 19Biopsy 18Cyclophosphamide 7venetoclax 5Vincristine 5Bevacizumab 5Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Azacitidine 4pembrolizumab 3fludarabine phosphate 3decitabine and cedazuridine drug combination 3X-Rays 3Taxes 3Radiosurgery 3Radiation 3Prednisone 3Injections 3Doxorubicin 3Cetuximab 3zanubrutinib 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2fludarabine 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × 1,2-diaminocyclohexaneplatinum II citrate × 90 days × Clear all
NCT05050162 2026-05-07

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NRG Oncology

Phase 2/3 Suspended
1,714 enrolled
Head & Neck

Carcinoma, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡